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Abstract
Background: Adequate prediction of survival plays an important role in treatment decisions for patients with spinal
bone metastases (SBM). Several prognostic factors are already used in daily clinical practice, but factors related to
stability of SBM are still unknown. Therefore, we designed this study to identify these prognostic factors.
Methods: We retrospectively assessed 915 patients from solid tumors with commonly metastased into the bone
treated at our department between January 2000 and January 2012. Lung cancer (NSCLC), breast and renal cancer
listed in Table 1 are the most common solid tumors with bone metastasis in this study. Prostate carcinoma was
excluded due to osteoblastic SBM with no influence for stability. We calculated overall survival (OS) and bone
survival (BS; time between first diagnosis of bone metastases until death) with the Kaplan-Meier method and
assessed prognostic factors for BS with the log-rank test and a Cox regression model separately for patients with
stable and unstable SBM.
Results: Median follow-up was 9.3 months. OS after 6 months, 1, 2, and 5 years was 81, 62, 42, and 25 % in patients
with stable SBM and 78, 57, 38, and 22 % in patients with unstable SBM (p = 0.851). BS was 57, 38, 22, and 5 % in
the group of stable SBM after 6 months, 1, 2, and 5 years. For patients with unstable SBM BS after 6 months, 1, 2,
and 5 years was 59, 39, 19, and 8 % (p = 0.755). In multivariate analysis we found male gender (HR = 1.27 [95 % CI
1.01–1.60], p = 0.04), Karnofsky performance status (KPS) <80 % (HR = 1.27 [95%CI 1.04–1.55], p = 0.02) and non-
small cell lung cancer (NSCLC; HR = 2.77 [95%CI 1.99–3.86], p < 0.0001) to be independent prognostic factors for
shortened survival in patients with stable SBM. Independent prognostic factors for unstable SBM were age per
year (HR = 1.01 [95 % CI 1.0–1.02], p = 0.025), multiple SBM (HR = 1.35 [95 % CI 1.1–1.65], p = 0.003), and NSCLC
(HR = 2.0 [95 % CI 1.43–2.80], p < 0.0001). Additionally, not wearing an orthopedic corset (HR = 0.77 [95 % CI 0.62–0.96],
p = 0.02) was associated with prolonged BS in patients with unstable SBM and in both groups BS was significantly
longer in patients without liver metastases (stable SBM: HR = 0.72 [95 % CI 0.56–0.92], p = 0.008; unstable SBM: HR = 0.
71 [95 % CI 0.54–0.92], p = 0.01).
Conclusions: Survival was equal for patients with stable and unstable SBM. However, prognostic factors differed in
both groups and stability should therefore be considered in treatment decision-making.
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Background
Bone metastases occur in different types of human can-
cer. Particularly patients with breast cancer, prostatic
cancer, and lung cancer in advanced stages have an in-
creased risk to suffer from bone metastases [1]. Most are
located in the vertebral column. Prognostic factors such
as gender, age, primary site, and Karnofsky performance
status (KPS) are already used in daily clinical practice
and have a strong influence on treatment decisions for
patients with spinal bone metastases (SBM) [2, 3]. How-
ever, prognostic factors related to stability of SBM are
still unknown and may differ between both groups.
Previous studies reported that the number of bone
metastases, pain, and primary tumor histology represent
significant prognostic factors [4]. It has also been shown
that early initiation of palliative treatment stabilizes the
bone, reduces pain and may prolong survival [5, 6].
Radiotherapy (RT) is one of the most important pillars
in the treatment of bone metastases and the indications
for palliative RT are: pain, existing or impending instabil-
ity, neurological symptoms or spinal cord compression
and adjuvant RT after surgical stabilization and interven-
tion. An approved scoring system for survival after RT
related to stability of SBM is still unknown [7].
Recently, factors such as KPS and patient-reported
pain scores have been discussed for several types of
cancer. However, KPS was not predictive for survival
in patients with painful SBM from non-small cell
lung cancer in a recent retrospective study [8]. Exist-
ing prognostic models in palliative radiation therapy
proposed by Chow et al. or van der Linden et al.
have still not been incorporated into daily practice
[9, 10]. In 2005, the Dutch bone metastasis study de-
veloped a scoring system in 342 patients with painful
bone metastases, but there were no data on bone
stability [10].
Adequate prediction of survival plays an important
role in treatment decisions for patients with SBM. The
objective of our retrospective study was to assess prog-
nostic factors for survival related to stability of SBM and
this study including 915 patients is the first to investi-
gate these factors.
Methods
A retrospective chart review was carried out including
915 patients whose bone lesions were treated by RT
at our department. They underwent RT for osteolytic
metastases of the vertebral column due to histologi-
cally diagnosed carcinoma in the period from January
2000 up to January 2012. The diagnosis of SBM was
based on computed tomography (CT) scans, magnetic
resonance imaging (MRI), or bone-scintigraphy inves-
tigations. Patients were examined using CT prior to
RT and were included in this retrospective analysis
based on the following criteria: RT performed in the
segments afflicted, osteolytic metastases, localization
in the thoracic and lumbar spine. Accordingly, 915
patients presenting bone lesions in the thoracic
(62 %) and lumbar (38 %) spine were evaluated. Many
patients exhibited more than one treated lesion. In
those cases only one lesion, which seemed essential
for stability, per vertebral body was included in the
analysis. The patient data were taken from the Heidel-
berg NCT Cancer Registry. The Heidelberg Ethics Com-
mittee approved this study on 22 October 2012. Due the
retrospective design, informed consent was not required.
Patients’ characteristics
Out of the 915 patients, 455 cases (49.7 %) were clas-
sified as unstable. The stability of each affected verte-
bral body was defined as pedicle involvement or
osteolytic lesion over 60 % of the vertebral body.
Patients were evaluated using CT imaging recorded
before RT to plan treatment and at the 3 and 6 month
follow-up examinations [11].
Patients’ mean age at diagnosis of SBM was 63 years
(+11 years). Gender was balanced with 498 male pa-
tients (53 %) and 426 female patients (47 %). In 46 %
of the patients KPS was lower than 80 %. The most
frequent (46 %) primary site was non-small cell lung
cancer (NSCLC), followed by breast cancer (20 %). In
62 % of the patients (n = 563) the thoracic spine was
involved, in 38 % (n = 352) the lumbar spine. The
study involved 417 patients (46 %) with solitary me-
tastases, while in 498 patients (54 %) multiple verte-
bral bodies were affected. More than half of all
patients were treated with bisphosphonates (71 %)
and/or received chemotherapy (CHT) prior to RT
(55 %). Almost half of the patients (48 %) were
prescribed an orthopedic corset (Table 1).
Radiotherapy
After virtual simulation was performed to plan the ra-
diation schedule, RT was carried out over a dorsal
photon field with the energy 6 MV. The photon field
covered the specific vertebral body affected as well as
the ones immediately above and below. Most of the
patients (72 %; n = 663) were treated with 10 × 3 Gy,
89 patients with 14 × 2.5 Gy, 150 patients with 20 ×
2 Gy, and 13 patients with other individual doses.
The median individual dose in all patients was
3.0 Gy, the median total dose was 30 Gy. The indi-
vidual and total doses were calculated separately for
each individual patient, depending on the histology,
the patient’s general state of health, the current staging
and the respective prognosis.
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Statistical analysis
The empirical distribution of continuous variables is
described by number of observations, mean and
standard deviation; the description of categorical vari-
ables includes the number and percentage of patients
belonging to the relevant categories. “Bone survival”
(BS) was defined as the time from initial diagnosis of
SBM until death. The time of site irradiation was not
equal to the time of initial diagnosis of SBM. Bone
metastases distal to the irradiated site were not in-
cluded. Overall survival (OS) was defined as time
from initial diagnosis of cancer until death. We esti-
mated patient survival using the Kaplan–Meier
method. Patients were censored on the basis of
whether or not they were alive. The univariate log-
rank test was used to evaluate the prognostic import-
ance of age, gender, localization of metastases, KPS,
breast cancer, NSCLC, renal cancer, liver metastases,
cerebral metastases, lung metastases, skin metastases,
CHT prior to RT, number of bone metastases,
bisphosphonates, orthopedic corset and RT schedule.
Results were reported as the p-values of the log-rank
tests. Multivariate analysis was performed to detect
factors independently associated with BS using a Cox
regression model. This regression analysis was per-
formed by inclusion of all clinical characteristics. The
results are reported as p-values, hazard ratios (HR)
and 95 % confidence intervals (CI). For all analyses, a
p-value of 0.05 or less was considered significant (cor-
rection factor for multiple tests). All statistical
Table 1 Patients‘ characteristics
Stable metastases Unstable metastases All patients p-value
n % n % n %
Age (years) Mean (SD) 61.8 +/− 11.0 63.7 +/− 11.0 62.7 +/− 11.1 0.973
Gender Male 246 50 243 50 489 53 0.983
Female 214 50 212 50 426 47
KPS <80 195 46 227 54 422 46 0.023
> = 80 265 54 228 46 493 54
Primary site
NSCLC 211 50 214 50 425 46 0.038
Breast cancer 83 47 92 53 175 20
Renal cancer 72 45 87 55 159 17
Other 94 60 62 40 156 17
Localization metastases
Thoracic 275 49 288 51 563 62 0.275
Lumbar 185 53 167 47 352 38
Number metastases
Solitary 243 58 174 42 417 46 <0.001
Multiple 217 44 281 56 498 54
Other distant metastases
Liver 102 55 84 45 186 20 0.163
Brain 71 56 56 44 127 14 0.176
Lung 111 58 81 42 192 21 0.019
Skin 26 72 10 28 36 4 0.007
Bisphosphonates 327 51 320 49 647 71 0.801
Chemotherapy 266 53 236 47 502 55 0.065
Orthopedic corset 140 32 302 68 442 48 <0.001
Radiotherapy schedule
10 × 3 Gy 349 53 314 47 663 72 0.092
14 × 2.5 Gy 36 40 53 60 89 10
20 × 2 Gy 68 45 82 55 150 16
Other 7 54 6 46 13 1
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analyses were done using the SAS software version
9.3 (SAS Institute, Cary, NC, USA).
Results
The median follow up of all patients was 9.3 months
with a mean of 12.2 (range 0.4–130.1 months). OS
rates after 6 months, 1, 2, and 5 years were 81, 62,
42, and 25 % in the group with stable SBM and 78,
57, 38, and 22 % in the group with unstable SBM re-
spectively (Fig. 1). BS, in the group with stable SBM,
was 57 % after 6 months, 38 % after 1 year, 22 %
after 2 years, and 8 % after 5 years. In the group with
unstable SBM BS was 59 % after 6 months, 39 %
after 1 year, 19 % after 2 years, and 8 % after 5 years
respectively (Fig. 2). At last follow-up 25 % of the pa-
tients with stable metastases and 22 % of the patients
with unstable metastases were still alive. There was
no statistically significant difference between both
groups, neither in OS nor in BS (Table 2).
In both groups, patients with stable and unstable
SBM, we found male gender (p < 0.001; p < 0.001),
KPS <80 % (p < 0.001; p = 0.046), multiple osseous
metastases (p = 0.027; p = 0.001), breast cancer (p <
0.001; p = 0.019), NSCLC (p < 0.001; p < 0.001), renal
cancer (p < 0.001; p < 0.001) and wearing an ortho-
pedic corset (p = 0.045; p = 0.002) to be statistically
associated with shortened bone survival.
Multivariate analysis identified various independent
prognostic factors for BS in patients with stable and
unstable metastases. Risk factors in stable SBM were
male sex with HR = 1.27 [CI 95 % 1.01–1.60], p =
0.04; KPS < 80 % with HR = 1.27 [CI 95 % 1.04–1.55],
p = 0.02; and NSCLC with HR = 2.77 [CI 95 % 1.99–
3.86], p < 0.0001. Risk factors in unstable SBM were
age per year with HR = 1.01 [95 % CI 1.0–1.02], p =
0.025; number of metastases >1 with HR = 1.35 [95 % CI
1.1–1.65], p = 0.003; and NSCLC with HR = 2.0 [95 % CI
1.43–2.80], p = <0.0001. Additionally, patients with un-
stable SBM who did not were an orthopedic corset had a
statistically prolonged BS (HR = 0.77 [95 % CI 0.62–0.96],
p = 0.02), and in both groups BS was significantly longer
in patients without liver metastases (stable SBM: HR =
0.72 [95 % CI 0.56–0.92], p = 0.008; unstable SBM:
HR = 0.71 [95 % CI 0.54–0.92], p = 0.01) (Table 3).
CHT prior to RT, localization of metastases,
concomitant bisphosphonates as well as the radiother-
apy schedule did not statistically significantly influ-
ence BS in both groups.
Discussion
Gender, primary site, age and KPS are well known
prognostic factors in tumor disease. However, prog-
nostic factors for survival related to initial stability of
SBM are still unknown. Therefore, the objective of
this retrospective study with 915 patients was to as-
sess prognostic factors for survival related to stability
of SBM. Adequate prediction of survival is important
in deciding on treatment for patients with SBM. In
our study we found no difference in BS or OS be-
tween patients with stable and unstable SBM. This is
in agreement with previous reports in which stability
did not influence survival. Neither in lung cancer,
with an extremely short survival time [8], nor in
breast cancer, with a significantly better prognosis
[12], did stability of SBM effect survival times. How-
ever, we were able to show that prognostic factors for
bone survival differ between patients with stable and
unstable metastases. For stable SBM gender, KPS, and
Fig. 1 Overall survival of patients with stable and unstable spinal bone metastases
Wolf et al. BMC Cancer  (2016) 16:528 Page 4 of 7
primary site were identified as prognostic factors.
Number of metastases, age, primary site, and wearing
of an orthopedic corset were prognostic factors in pa-
tients with unstable SBM. In both groups visceral me-
tastases, particularly liver metastases, were associated
with a significantly shorter survival. Previous studies
on prognostic factors for survival after diagnosis of
bone metastases support our result. A recent study
identified five factors in elderly breast cancer patients
as independent predictors of survival: visceral metas-
tases, time developing motor deficits, ambulatory sta-
tus, performance score, and number of involved
vertebrae [2, 13]. In another previous study symptom-
atic spinal metastases, pretreatment albumin level,
primary cancer site, KPS, and number of visceral me-
tastases were associated with survival [3]. 46 % of the
patients in our study suffered from lung cancer
(NSCLC), most of which were males, with a poor
prognosis whether the bone lesions are stable or un-
stable [8]. On the other hand women with breast can-
cer, 20 % in our study, have a better prognosis in BS
and OS [12]. Patients with multiple bone metastases
[14] are frequently those requiring an orthopedic cor-
set. The additionally immobilization may worsen mor-
bidity and quality of life in those patients, which in
turn could explain the significantly reduced survival
probability. In a recent study we demonstrated that
the incidence of pathological fractures is not signifi-
cantly increased without a surgical corset [15]. We
thus believe that clinicians should focus more on pa-
tients’ individual situations when prescribing surgical
corsets. Concomitant bisphosphonate treatment did
not influence survival in our analysis. We believe that
the median follow-up of 9.3 months might have been
too short to detect any effects of bisphosphonate
therapy. In a study in 2004 bisphosphonate therapy it-
self contains a 9-months core phase and a 12-months
extension phase. The final analysis in this study was
performed at 21 months after therapy. Here median
time to first skeletal-related events was prolonged by
nearly 4 months, so we conclude the benefit for
stability can only be demonstrated in a longer
follow-up [16].
This study is focusing on stability and survival
time, thus other factors such as pain, quality of life,
neurologic indication, data on additional osteolytic
or osteoblastic lesions, operative stabilization, co-
morbidity, pathologic fractures or incidence of new
metastases are not recorded in this analysis. This
should be included in further investigations. Data on
time between first diagnosis of cancer and first
Fig. 2 Bone survival of patients with stable and unstable spinal bone metastases
Table 2 Overall survival and bone survival
Stable metastases Unstable metastases p-value
Overall survival % % 0.851
6 months 81 78
1 year 62 57
2 years 42 38
5 years 25 22
Bone survival % % 0.755
6 months 57 59
1 year 38 39
2 years 22 19
5 years 8 8
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diagnosis of bone metastases were not available in
the dataset. Therefore, this analysis cannot differenti-
ate between patients with early or late onset metas-
tases. However, in ovarian cancer diagnosis of late-
onset bone metastases hardly influenced the prognosis at
all [17].
This study underlined that limited disease, male
gender, age, performance status and certain primary
Table 3 Influence of potential prognostic factors on bone survival in multivariate analysis
Stable metastases Unstable metastases
Factor Hazard Ratio 95 % CI p-value Hazard Ratio 95 % CI p-value
Age 1.01 0.99–1.02 0.09 1.01 1.00–1.02 0.025
Gender
Female Reference
Male 1.27 1.01–1.60 0.04 1.07 0.83–1.38 0.59
KPS
> =80 % Reference
< 80 % 1.27 1.04–1.55 0.02 1.11 0.91–1.35 0.30
Primary site
Breast cancer Reference
NSCLC 2.77 1.99–3.86 <0.0001 2.00 1.43–2.80 <0.0001
Renal cancer 0.84 0.53–1.33 0.47 0.85 0.54–1.33 0.47
Localization of metastases
Thoracic Reference
Lumbar 1.07 0.87–1.31 0.53 0.90 0.73–1.11 0.31
Number of metastases
1 Reference
> 1 1.16 0.95–1.41 0.13 1.35 1.11–1.65 0.003
Other distant metastases
Liver yes Reference
no 0.72 0.56–0.92 0.008 0.71 0.54–0.92 0.003
Brain yes Reference
no 0.84 0.63–1.11 0.22 0.85 0.63–1.16 0.32
Lung yes Reference
no 1.27 0.99–1.62 0.06 1.05 0.79–1.40 0.73
Skin yes Reference
no 1.09 0.69–1.72 0.71 0.91 0.44–1.85 0.79
Bisphosphonates
yes Reference
no 1.19 0.91–1.56 0.21 1.07 0.79–1.44 0.66
Chemotherapy
yes Reference
no 0.84 0.68–1.02 0.08 0.97 0.79–1.19 0.79
Orthopedic corset
yes Reference
no 0.84 0.67–1.06 0.14 0.77 0.62–0.96 0.02
Radiotherapy schedule
> 30 Gy Reference
< =30 Gy 1.27 0.99–1.63 0.06 1.08 0.86–1.35 0.53
Data in bold p-value <0.05 are significant statistically
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sites such as NSCLC are prognostic factors for sur-
vival. Importantly, prognostic factors differed between
patients with stable und unstable SBM. Therefore,
stability should be considered in treatment decision-
making, despite that BS and OS did not differ
between patients with stable and unstable SBM.
Conclusion
This study found no difference in BS or OS between
patients with stable and unstable SBM in different types
of cancer. However, prognostic factors differed between
both groups and stability should be considered in treatment
decision-making.
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